Riffyn Highlighted in Forbes - Five Things Big Pharma — and Its Investors — Could Learn from Synthetic Biology
Riffyn got its start in the synthetic biology space. It even landed its first major customer (Novozymes) at a SynBioBeta conference. Recently, SynBioBeta’s CEO John Cumbers caught up with Tim about Riffyn on his Forbes column in a piece entitled “Five Things Big Pharma -- and Its Investors -- Could Learn from Synthetic Biology.” In the article Cumbers asks Riffyn CEO, Tim Gardner, what he thinks are five lessons he’s learned in synthetic biology and biomanufacturing that biopharma should hear. Curious to know what he said? Read the article on Forbes.
Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of traditional scientific data systems — delivering results that are always ready for machine learning.